Pragmatic Trials for Noncommunicable Diseases: Relieving Constraints

Access status:

Open Access

Field	Value	Language
dc.contributor.author	Patel, A
dc.contributor.author	Webster, R
dc.date.accessioned	2019-09-11
dc.date.available	2019-09-11
dc.date.issued	2016-03-01
dc.identifier.citation	Patel, A., & Webster, R. (2016). Pragmatic Trials for Noncommunicable Diseases: Relieving Constraints. PLOS Medicine, 13(3), e1001986. https://doi.org/10.1371/journal.pmed.1001986	en
dc.identifier.uri	http://hdl.handle.net/2123/21099
dc.description.abstract	At the 65th World Health Assembly in 2012, all World Health Organization member states made a historic commitment to reduce premature deaths from noncommunicable diseases (NCDs, including cardiovascular diseases, diabetes, cancer, and chronic respiratory diseases) by 25% by 2025. Subsequently, the World Health Assembly in 2013 agreed to adopt a global monitoring framework that included nine ambitious global NCD targets for 2025 [1]. These targets address key risk factors including tobacco and alcohol use, physical inactivity, high salt intake, high blood pressure, diabetes, and obesity and also the availability of basic technologies and medicines for the prevention and treatment of major NCDs.	en
dc.language.iso	en_AU	en
dc.publisher	Public Library of Science	en
dc.relation	n/a	en
dc.rights	Other
dc.title	Pragmatic Trials for Noncommunicable Diseases: Relieving Constraints	en
dc.type	Article	en
dc.identifier.doi	10.1371/journal.pmed.1001986
dc.type.pubtype	Publisher's version	en
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en

Associated file/s